The Annals of Applied Statistics
- Ann. Appl. Stat.
- Volume 5, Number 2A (2011), 924-942.
Bayesian phase I/II adaptively randomized oncology trials with combined drugs
We propose a new integrated phase I/II trial design to identify the most efficacious dose combination that also satisfies certain safety requirements for drug-combination trials. We first take a Bayesian copula-type model for dose finding in phase I. After identifying a set of admissible doses, we immediately move the entire set forward to phase II. We propose a novel adaptive randomization scheme to favor assigning patients to more efficacious dose-combination arms. Our adaptive randomization scheme takes into account both the point estimate and variability of efficacy. By using a moving reference to compare the relative efficacy among treatment arms, our method achieves a high resolution to distinguish different arms. We also consider groupwise adaptive randomization when efficacy is late-onset. We conduct extensive simulation studies to examine the operating characteristics of the proposed design, and illustrate our method using a phase I/II melanoma clinical trial.
Ann. Appl. Stat., Volume 5, Number 2A (2011), 924-942.
First available in Project Euclid: 13 July 2011
Permanent link to this document
Digital Object Identifier
Mathematical Reviews number (MathSciNet)
Zentralblatt MATH identifier
Yuan, Ying; Yin, Guosheng. Bayesian phase I/II adaptively randomized oncology trials with combined drugs. Ann. Appl. Stat. 5 (2011), no. 2A, 924--942. doi:10.1214/10-AOAS433. https://projecteuclid.org/euclid.aoas/1310562211